1-3 of 3
Christopher Tehlirian
Close
Sort by
Journal Articles

BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study

David Lavie, Vincent Ribrag, Michael Loschi, Costas K. Yannakou, Maan Alwan, Adi Schacham Abulafia, Jesús María Hernández-Rivas, Yulia Volchek, Chun Yew Fong, Massimiliano Bonifacio, Jean-Jacques Kiladjian, Jean-Christophe Ianotto, Valentín García Gutiérrez, Alessandra Tucci, Blanca Xicoy, Haifa Kathrin Al-Ali, Moshe Talpaz, Jonathan M. Gerber, Indu Raman, Ciprian Tomuleasa, Si Tuen Lee-Hoeflich, Sharmila Das, Bin Wu, Qian Zhao, Eunhee Kim, Oriana Esposito, Yu Liu, Zariana Nikolova, Christopher Tehlirian, Shodeinde Coker, Rosa Ayala
Journal: Blood
Blood (2023) 142 (Supplement 1): 623.
https://doi.org/10.1182/blood-2023-179160
Published: 2023
Journal Articles

Modulation of Biomarkers By BET Inhibitor, BMS-986158, Including JAK2 Variant Allele Frequency (VAF), Bone Marrow (BM) Fibrosis, and Reversal of Abnormal Cytokine Production in Intermediate- or High-Risk Myelofibrosis (MF)

Si Tuen Lee-Hoeflich, Christopher Brueckner, Lawrence Litalien, Ke Xu, Sharmila Das, Laura Corella, Sherif Daouti, Oriana Esposito, Emma Lees, Yu Liu, Zariana Nikolova, Christopher Tehlirian, Shodeinde Coker, Bin Wu
Journal: Blood
Blood (2023) 142 (Supplement 1): 3158.
https://doi.org/10.1182/blood-2023-181620
Published: 2023
Journal Articles

BMS-986158, a Potent BET Inhibitor, As Monotherapy and in Combination with Ruxolitinib or Fedratinib in Intermediate- or High-Risk Myelofibrosis: First Results from a Phase 1/2 Study

Rosa Ayala, Nieves Lopez, Adi Shacham Abulafia, Maan Alwan, Costas K. Yannakou, Indu Raman, Vincent Ribrag, Chun Yew Fong, Yulia Volchek, Massimiliano Bonifacio, Alessandra Tucci, Jean-Jacques Kiladjian, Henry Chang, Sharmila Das, Bin Wu, Palanikumar Ravindran, Vivian Shan, Guan Wang, Oriana Esposito, Yu Liu, Zariana Nikolova, Christopher Tehlirian, Shodeinde Coker, David Lavie
Journal: Blood
Blood (2022) 140 (Supplement 1): 9665–9667.
https://doi.org/10.1182/blood-2022-159476
Published: 2022